Drugs / DTPa-HBV-IPV+Hib
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT06213506 Background | Jan 2024 → Aug 2026 | salmonellosis | GlaxoSmithKline | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DTPa-HBV-IPV+Hib | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06213506 ↗ |
| Modality | Vaccine | “DTPa-HBV-IPV+Hib vaccine” NCT06213506 ↗ |
| Route | Intramuscular | “administered intramuscularly” NCT06213506 ↗ |